Evidence map›Paper›PMID 19263237›Full record

ReviewJournal of inherited metabolic disease2009

Animal models of maple syrup urine disease.

K J Skvorak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of inherited metabolic disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Metabolic pathways at the crossroads of diabetes and inborn errors.Journal of inherited metabolic disease · 2018
    Review
  2. Article
  3. [Maple syrup urine disease and gene mutations in twin neonates].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. BCATm deficiency ameliorates endotoxin-induced decrease in muscle protein synthesis and improves survival in septic mice.American journal of physiology. Regulatory, integrative and comparative physiology · 2010
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

K J SkvorakGraduate Program in the Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA, USA. kjskvorak@gmail.com
University of Pittsburgh Medical Center · US

Funding

CONDITIONAL MURINE MODEL OF MAPLE SYRUP URINE DISEASER43DK057956 · NIDDK · BIOMED RESEARCH AND TECHNOLOGIES, INC. · PI PAUL, HARBHAJAN S · 2000 to 2000
$100k
GENE THERAPY FOR MAPLE SYRUP URINE DISEASER43DK057386 · NIDDK · BIOMED RESEARCH AND TECHNOLOGIES, INC. · PI PAUL, HARBHAJAN S · 2000 to 2000
$100k
NIDDK NIH HHS R43DK57386NIDDK NIH HHS R43DK57956
6 · The paper itself

Abstract

Maple syrup urine disease (MSUD) is an inherited aminoacidopathy resulting from dysfunction of the branched-chain keto acid dehydrogenase (BCKDH) complex. This disease is currently treated primarily by dietary restriction of branched-chain amino acids (BCAAs). However, dietary compliance is often challenging. Conversely, liver transplantation significantly improves outcomes, but donor organs are scarce and there are high costs and potential risks associated with this invasive procedure. Therefore, improved treatment options for MSUD are needed. Development of novel treatments could be facilitated by animal models that accurately mimic the human disease. Animal models provide a useful system in which to explore disease mechanisms and new preclinical therapies. Here we review MSUD and currently available animal models and their corresponding relevance to the human disorder. Using animal models to gain a more complete understanding of the pathophysiology behind the human disease may lead to new or improved therapies to treat or potentially cure the disorder.

Indexed as

3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)Amino Acids, Branched-ChainAnimalsBrainCattleDietDisease Models, AnimalLiverMaple Syrup Urine DiseaseMiceMice, KnockoutMice, Transgenic3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)Amino Acids, Branched-Chain

Identifiers

PMID19263237
OpenAlexW2024245010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.